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A B S T R A C T   
Huge amounts of genomic data produced by researchers around the world undermine data-centred discovery and 
therapeutic development. This paper considers how researchers make decisions about the actionability of specific 
datasets and the conditions that allow such data to be trusted. We discuss the case of COSMIC, a leading cancer 
genomics database which aggregates a large amount of sources. We research what the actionability of cancer 
data means in different situations of use, contrasting exploratory and diagnostics research. They highlight 
different questions and concerns upon genomic data use in medical research. At the same time, strategies and 
justifications pursued to evaluate and re-use can also share important similarities. To explain differences and 
similarities, we argue for an understanding of actionability and trust in data that depends on the goals and re-
sources within the situation of inquiry, and the social epistemology of standards.   
1. Introduction 
The vision of clinical advancement offered by precision medicine 
implicates a large number of elements (Keating and Cambrosio 2011, 
2013; Prainsack 2020). In oncology, where precision medicine has been 
heavily promoted over the last decade, these include overarching 
epistemic frameworks, data sources, technologies, organisational pro-
cesses, strategic partnerships, experts, capital investments, legal and 
policy frameworks, drugs and algorithms (Cambrosio et al., 2013; Hogle 
2016; Levin 2018; Vignola-Gagné et al., 2017). Against this background, 
this paper highlights the challenges involved in the evaluation and use of 
sequencing research data in the development of innovative oncological 
diagnostics and treatments, focusing particularly on the impact of data 
management procedures and decisions on data interpretation. We argue 
that data infrastructures shape data interpretation and facilitate users’ 
trust in the actionability of data as evidence for future applications of 
genomic innovations in clinical settings – an achievement involving a 
degree of informed speculation about the quality and significance of 
data. 
Genomic data are among the best standardised and most valued data 
types available to precision medicine. Yet they require complex 
intermediations to be used as medical evidence (Rheinberger 2010), 
including curation and visualisation practices that make it possible for 
these data to move across user communities (Lowe 2018). This consid-
erably complicates the interpretation of genomic sequences (Huang 
et al., 2016). In what follows, we document the efforts involved in 
maintaining the Catalogue of Somatic Mutations in Cancer (COSMIC), a 
database developed to distribute research evidence on associations be-
tween genetic sequences and specific cancer types, susceptibility to 
targeted treatments and other functional implications (Bamford et al., 
2004; Tate et al., 2019). COSMIC is widely regarded as a key resource for 
achieving reliable interpretations of genomic data and related mutations 
in oncology. An investigation of COSMIC curatorial practices and their 
reception by COSMIC users provides an excellent window into practices 
of genomic data management, evaluation and use within oncology (see 
also Tempini, 2020a). 
Finding evidence that suggests that a given mutation is associated 
with a specific cancer type is a common heuristic strategy for developing 
mechanistic hypotheses on the drivers of the disease (Bechtel 2019). 
However, current understandings of the causal role of particular genes 
and mutations – and more generally the aetiology of cancer – remain 
limited and contested (Bertolaso 2016; Plutinsky 2018). Consequently, 
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it is difficult to decide how to take action and what to target – an issue 
typically referred to as actionability by practitioners. Actionability cap-
tures the “aim to generate predictive relationships between genetic infor-
mation and drug therapies” (Nelson et al., 2013:405) in a context where 
there is no straightforward pairing between observed sequences and 
definitive assessment of cause and trajectory of the individual cancer. 
Crucially, making genetic mutation data actionable depends on the 
constraints posed by related socio-technical systems – and several such 
considerations are involved when assessing alternative courses of action, 
“such as the regulatory status of those mutations and drugs, the availability of 
testing and treatments within health care systems, and the geographical 
location and design of clinical trials for drugs still under development” 
(Nelson et al., 2013:414). Actionability has a strong organisational 
connotation, highlighting the implications of data for division of labour 
(407). Given the current data deluge, researchers have no choice but to 
resort to databases of genomic evidence and the interpretive decisions 
that have been embedded within them (Timmermans 2015). 
This paper discusses epistemic assessments of data actionability by 
COSMIC curators and users, with a particular interest in data practices 
and the organisational interdependencies that shape them (Leonelli, 
2016; Tempini, 2017, 2020a). We explore the concept of data action-
ability in contexts other than clinical settings, thus contributing to 
studies of genomic evidence in oncology and the associated epistemo-
logical, ethical and professional uncertainties (Bergeron et al., 2020; 
Bergeron and Castel, 2011; Cambrosio et al., 2020; Kerr et al., 2019; 
Timmermans et al., 2017). Clinical situations are complex (hence the 
emergence of Molecular Tumour Boards, where different specialists 
convene – Bourret and Cambrosio 2019) and many steps of data pro-
duction and manipulation separate the initial clinical encounter from 
the diagnostic and therapeutic response. Our study focuses on one spe-
cific fragment of the genomic medicine mosaic. We analyse the condi-
tions for the actionability of COSMIC data in light of two concepts 
informed by previous work in the social studies of science: speculative 
reasoning and trust. Our analysis aims to show how assessments of 
actionability are tied to both these concepts. 
By speculative reasoning we mean the process whereby the persis-
tent uncertainty related to genomic sequences is harnessed and trans-
formed into possibility, promise and opportunity. This enables the 
emergence of a research and innovation industry. As Fortun (2008) ar-
gues, a genomic industry is sustainable if it is able to promise a ‘revo-
lution’ in medicine and envision and articulate the key milestones, 
resources, and methods that will enable it. Our use of the concept fol-
lows Fortun in that speculation is not simply a discursive notion – a way 
of reasoning about epistemic uncertainty by way of hypotheticals and 
assumptions. Nor is it reducible to a materialist concept grounded in 
risk-taking, material and financial commitments, and rewards. Instead, 
we understand speculation as a twofold concept within which these 
discursive and materialist interpretations are inseparable and sustain 
each other (Fortun, 2008). When exception rules, the absence of defin-
itive evidence enables actions based upon incomplete assumptions 
(Fortun, 2008; Kerr et al., 2019). Hence, uncertainty is productive 
(Timmermans et al., 2017). It also opens the possibility for different 
initiatives to interface with one another while developing in-
terdependencies and operationalising assumptions. Partaking in a 
regime of innovation grounded on the promise of a future in the making 
(Rajan 2006; Fortun 2008; Hilgartner 2017), the production of specu-
lative judgements about the importance of specific mutation data is a 
key element of data curation in databases like COSMIC. Curators who 
retrieve and harvest published data must judge which are worth adding 
to and maintaining in the database. This form of ‘speculation’ happens in 
the midst of the deafening ‘noise’ generated by the observation of a 
multitude of mutations, which can impede the search for any ‘signal’. In 
this sense, the enterprise of curation will be shown to be about enabling 
data-based decisions and actions in under-specified situations of subse-
quent use. 
The other key concept is trust. COSMIC data are used as a standard 
for the functional interpretation of mutations by several teams and or-
ganisations operating in cancer genomic medicine, including some of 
the most prominent cutting-edge systems. For instance, the Memorial 
Sloan Kettering Cancer Centre’s cBioPortal integrates COSMIC data as 
one of several layers of data that in-house clinicians juxtapose to indi-
vidual cancer profiles (Gao et al., 2013). And research and diagnostics 
services company Personal Genome Diagnostics, a Johns Hopkins’ 
spin-off, performs comparisons of sequenced sample data to COSMIC as 
part of its routines (see Fig. 1) (Jones et al., 2015). The COSMIC team has 
published many papers that have been cited thousands or many hun-
dreds of times (e.g., Bamford et al., 2004; Forbes et al., 2011; Forbes 
et al. 2015; Forbes et al. 2016; Forbes et al. 2017). 
The widespread reliance on the contributions of a single team is 
particularly interesting in light of the epistemic uncertainties involved in 
working on a complex and elusive disease. COSMIC data seem to func-
tion as terra firma upon which competing scientific efforts, navigating 
uncharted waters, can pivot and develop the innovations they lay claim 
to. In what ways do attitudes of trust towards COSMIC shape assessments of 
data actionability? How do researchers speculate on opportunities and risks 
linked to the use of a community standard such as the COSMIC database? By 
addressing these questions, this paper seeks to flesh out the relationship 
between data actionability, speculative reasoning and trust that char-
acterises data management practices in cancer genomics. 
Key STS work has investigated the conditions that allow researchers 
to trust heterogeneous evidence (e.g., Fortun 2008; Lynch et al., 2010; 
Porter 1995; Timmermans 2015). Here we focus on the considerations 
and concerns held by researchers involved in trusting, speculating, and 
acting with data: 1) that have been made available by curators who, in 
turn, are concerned with issues of trust, speculation and actionability of 
data sources; 2) that are routinely produced by an institution – COSMIC 
– that is devoted to data stewardship and the development of data 
infrastructure; and 3) whose access and reuse depends substantially on 
aligning data practices and infrastructures with that institution. We thus 
move across the gap separating curators and data users, to try and show 
how consequent experiences of genomic data work of curators and data 
re-using researchers inform and shape one another. We build on recent 
STS insights into standardization, data infrastructures and curation, 
trust and the role of evidence in personalised and precision medicine 
(Prainsack 2020; Cambrosio et al., 2020) to reveal some of the 
epistemic, organisational and infrastructural interdependencies that 
shape the circulation and actionability of cancer genomics data. 
2. Methods 
Our analysis is based on a qualitative study of COSMIC curation 
practices carried out between 2015 and 2017. This encompassed 
twenty-one interviews with team members and data users. With the 
exception of one, all interviews were carried out during two field visits 
by Tempini and over a total of six days. Interviews were semi-structured 
and followed a questionnaire that was customized for each interviewee 
on the basis of their professional and scientific background, organisa-
tional role and work context. These interviews were accompanied by 
some opportunities for on-site observation, including an exploratory site 
visit in 2015, participation in an awayday during which the COSMIC 
team and external collaborators presented their work and reflected on 
the state of the project, and informal discussions during a relevant 
workshop on data practices in bioinformatics and biomedicine in 
January 2017. The case study is also informed by secondary evidence 
gathered from the COSMIC website, browsing of available data re-
sources, associated documentation of procedures and standards, and the 
cancer genomics literature related to COSMIC. The aim of the fieldwork 
was to document perspectives and the roles of COSMIC staff in the 
development and assemblage of the COSMIC database, as well as the 
perspectives of users in bringing COSMIC to bear in their own data 
interpretation processes (cfr. Tempini 2020a). Those interview tran-
scripts which participants have agreed to disclose are accessible from the 
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Exeter Data Studies data collection hosted by Zenodo (Tempini 2020c; 
yExeter Data Studies). This case study is one of several carried out within 
a larger project on the impact of big data methods and infrastructures in 
the biological and biomedical sciences (www.datastudies.eu). 
COSMIC was chosen as an ideal research site for understanding data 
management practices in a fast-changing field of biomedical research. 
The opportunity for broader contextualization of research data practices 
provided by the parent project allowed us to restrict our focus to COS-
MIC curators and users. Through content analysis of the data we 
collected at COSMIC, we identified data curators’ concerns about the 
quality of the data stored in the database, the challenges of adhering to 
the curatorial standards of the project, and the strategies used to meet 
them. We also gathered user perspectives on the implications of related 
organisational procedures for the actionability of COSMIC data. Below, 
we report an analysis of these views and challenges supported by select 
interview excerpts. The analysis is intended to inform future research on 
how COSMIC impacts downstream clinical practice, a topic that which is 
beyond the scope of this paper. 
The paper is structured as follows. First we situate COSMIC in the 
field of precision oncology. We then report on team members, and 
users’, views; and we identify differences between the views and as-
sumptions held by data users working within exploratory research and 
within the field of diagnostics. We conclude by discussing, in light of 
philosophical and social scientific scholarship on trust in evidence and in 
Fig. 1. Schematic description of whole-exome or targeted next-generation sequencing analyses (from: Jones et al., 2015).  
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organisations (Hawley 2017; Porter 1995; Timmermans 2015), how 
users’ judgement of reliability of the data, speculative value, and 
actionability shape one another. The procedural standardization of 
curation processes and the status of COSMIC as a benchmark allow re-
searchers to rely on COSMIC data for their analytic processes, while at 
the same time ensuring that the evidence remains broadly in line with 
their own expert assumptions. 
3. The Catalogue of Somatic Mutations in Cancer (COSMIC) 
The Catalogue of Somatic Mutations in Cancer (COSMIC) is a project 
of the Sanger Institute based at the Wellcome Genome Campus in 
Hinxton, UK. It originated from a cancer genetics ‘list’, a spreadsheet 
curated by the principal investigators of the Institute’s Cancer Genome 
Project’s (CGP). Formalizing their knowledge and state of the art, this 
list contained several dozen entries on genes that, when mutated, are 
often implicated in human cancers. Later, it was published as the Cancer 
Gene Census (Futreal et al., 2004). In 2004, the idea of a gene-centric 
curation of cancer genetics research data was turned into a 
full-fledged web project, and COSMIC was created to promote the cir-
culation of research evidence in the community (Bamford et al., 2004). 
COSMIC launched with an extensive curation of the evidence for the role 
of four genes in cancer. In the following years, the focus shifted from 
cancer genetics to cancer genomics (Forbes et al., 2006, 2008). This 
required adjustments in data aggregation and dissemination strategies, 
since the then new genomic studies generated much bigger datasets. By 
2005, the number of genes curated by COSMIC has grown to 28. 
Importing new genomic data from CGP’s cancer cell lines then added a 
further 518 mutated genes from over 124,000 samples. The rapid 
growth continued: by 2008, genes in COSMIC counted over 4800 and 
sampled 250,000; in 2011, the counts were, respectively, over 18,000 
and 542,000; and in 2015, the number of samples exceeded one million 
(Forbes et al., 2006, 2008, 2011, 2015). “Originally designed to detail 
simple coding gene point mutations, COSMIC now describes millions of coding 
mutations, noncoding mutations, genomic rearrangements, fusion genes, copy 
number abnormalities and gene expression variants across the human 
genome” (Forbes et al., 2015:D805). As the volume and types of data 
kept multiplying, questions about what data are most important to the 
community resurfaced. Several integrations of COSMIC with other 
cancer databases were carried out, the genomic data of the consortia The 
Cancer Genome Atlas (TCGA) and International Cancer Genome Con-
sortium (ICGC) were imported, and interfaces with other bioinformatics 
infrastructures (e.g., Ensembl) developed (Forbes et al., 2011). 
COSMIC has since become widely used in precision oncology. 
Research teams and industry routinely produce genomic data from 
cancer samples and need a trustworthy reference with which to compare 
their data. COSMIC shows which mutated sequences were observed in 
other cancer patients and highlights potential associations with other 
observations and events. The increasingly complex and open-ended 
picture of the causative processes of cancer (Plutinsky 2018) has 
increased the need for such a point of reference for brokering research 
evidence. As COSMIC Director Simon Forbes put it, “We want to focus on 
supporting precision oncology as much as possible because, while a number 
of the mutations causing cancer are understood, quite a large number are 
considered potentially causing cancer, but no one quite knows how or why” 
(SF). A collection of cancer-related mutations assembled over fifteen 
years by a specialised team in a leading research institution, COSMIC 
provides an authoritative guide to research evidence. It helps the 
research community and companies to reduce duplication of effort and 
related costs. As a diagnostics researcher put it: “Every cancer company 
would be reinventing the wheel to try and filter out those common mutations. 
It’s better done in one place with one team so that people can benefit” (D1). 
By enabling cost-efficiency and procedural consistency while relieving 
its users of difficult decisions about how to source, aggregate and 
evaluate the evidence base, COSMIC has become a standard for cancer 
genomics (see Timmermans 2015). 
3.1. Data integration procedures 
The rigour of COSMIC’s data integration procedures is a consequence 
of standardization and specialization in the sourcing and curation of 
cancer genomic data. Members of the curation team focus on either of 
two processes, which they refer to as in-depth, manual, genic curation 
and broad, semi-automated, genomic curation, respectively. 
In the first kind of curation, post-doctoral researchers with a back-
ground in biology aim to curate all key papers that are published on 
genes they specialize in. A list of key genes is shared and periodically 
reviewed by the team of curators, who exchange insights into research 
trends, promising discoveries, and genes with growing evidence of 
implication in carcinogenesis. Each curator is responsible for curating 
evidence relating to a subset of genes. They receive a daily automated 
report of all new publications about any of ‘their’ genes. They read and 
extract data from papers and input them into COSMIC by means of a 
dedicated web interface. New curators are able to keep up with the 
literature published on just a few genes, while the most experienced may 
watch over the literature of several dozens. Manual curation is suited to 
generating deep and high-quality data. Papers deemed to be of high 
quality or promise are prioritized. Literature that adds evidence on 
already well-known relationships is of secondary importance and may 
not be curated. Curators need to carefully evaluate opportunities, and 
curate only the literature that yields the most value. Blindly curating all 
the papers published on a particular gene would be wasteful, as not all 
studies report novel evidence; at the same time, fixating on the same 
genes risks missing emerging trends. 
Coverage is a challenge for this kind of curation. The number of 
potentially relevant genes is enormous. Most mutations are thought to 
be a consequence of cancer. These are called ‘passenger’ as opposed to 
causative ‘driver’ mutations, but establishing which mutations are pas-
sengers and which may be drivers is laborious. The COSMIC team – nor 
any other cancer genomics team, to our knowledge – does not have the 
resources to manually curate all literature about all genes that are sus-
pected to play a role in cancer. At periodic meetings, the collective of 
curators discusses emerging trends and whether curators’ watch lists 
need updating, taking on genes not hitherto covered. Considerations 
shaping the selection of genes for curation may include evidence of 
causal effect as well as broader research trends, and whether new genes 
are ‘neighbours’ of already curated, ‘old’ genes – as publications about 
the latter often include or cite the former. A list of genes implicated in 
cancer causation, the Cancer Gene Census, has been maintained by 
COSMIC since its early years (Sondka et al., 2018). Upon periodic re-
view, genes can be ‘promoted’ or ‘demoted’ from the Cancer Gene 
Census. The list includes more genes than the team can manually curate 
and an attempt is made to distinguish mutated genes for which there is 
strong causal evidence from those for which evidence is unclear. The 
Census is an authoritative ‘hotlist’ of the most important mutated genes. 
COSMIC also incorporates data that are not manually curated. These 
data are acquired from whole-genome and gene-panel datasets. In this 
second type of data curation, post-doctoral researchers with program-
ming skills download data from repositories (e.g., The Cancer Genome 
Atlas) or from publications’ supplemental materials. They integrate such 
data into COSMIC by scripting code. Here, the emphasis is less on se-
lection of the curation sources and targets. Broad genomic data curation 
is an ‘agnostic’ process since the team is not integrating these data on the 
assumption of a relevant and potentially causative association of specific 
genes in carcinogenesis (as is the case with manual curation proced-
ures), but rather to make comprehensive datasets of mutations observed 
in cancer samples available in a trusted repository. A greater proportion 
of this imported data is about genes that are mutated as a result of cancer 
(‘passenger’ mutations) rather than as the cause of cancer (‘driver’ 
mutations), heightening the need to distinguish between data sources 
and mutation types. COSMIC updates are released every three months 
with a new version of the database. Emphasising standardization and 
data traceability, the team also publishes a summary of its curatorial 
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processes on COSMIC website. 
3.2. Making research data aggregation processes trustworthy 
COSMIC curators’ reflections in interviews are shaped by mounting 
pressures for COSMIC to publish reliable data. This is the result of 1) new 
uses developed for the data by the community on the back of method-
ological and theoretical innovations, and 2) the ballooning amounts and 
diversity of cancer research data being published. The staff regularly 
meet users, organise COSMIC training workshops, and attend interna-
tional conferences to understand which uses should be better supported, 
which kinds of data are most valuable and for whom, and how to 
improve their availability. The current business model, a hybrid of 
capped charitable funds and private fees, has opened the project to 
collaborations with private companies. These make the project more 
sensitive to the specific priorities of its partners but have also created a 
stable collaborative basis for understanding user needs and to access 
external expertise on complex translational questions. COSMIC’s pivotal 
position is founded on the maintenance of a core of well-curated data-
sets. As of 2015, over 30% of the papers examined by COSMIC curators 
had been rejected on quality grounds (Forbes et al., 2015). Standardised 
curation practices are also needed to evaluate which types of data do not 
fall within the current scope of curation at present but might become 
important in the future: ‘new’ genes that are not yet part of the set of 
curation targets, and new kinds of data, e.g., on drug resistance or 
methylation. 
In curating the genomic data deluge, some trade-offs are unavoid-
able. Human resources are limited, which constrains the choice of 
curation targets. Also, the research-orientation of the project creates 
tensions with respect to clinical applications of COSMIC data. The 
adoption of research-grade databases in the clinic always poses a degree 
of risk and concern. Curators can be anxious about the consequences of 
potential curation mistakes: “I really get worried about making mistakes. 
[…] If you’re going to be a good curator, and I think that does apply to other 
people in the office too, but you’ve got to … have a certain level of worry, or 
fear almost, of making a mistake […] I really check everything, and I prob-
ably spend a bit too long checking things, because then you don’t get quite as 
much done” (C1). Worries around quality revolve not only around what 
is included (errors, false positives and potential mis-categorizations), 
but also around what may have been omitted that should have been 
selected for inclusion (neglected discoveries, new data types). 
At the same time, the team’s concerns are not only related to whether 
data are ready for widespread publication as to the ways in which 
methodological caveats and foibles might be ignored, and the diversity 
of assumptions with which the data might be interpreted in specific 
situations of re-use. As COSMIC’s director puts it: “It’s what people have 
been wanting to do all along […] It’s also terrifying because everyone’s 
frightened of bringing broadly research informatics and analytics to a clinical 
space, but as long as that’s only part of the decision-making process then 
that’s probably sensible” (SF). The COSMIC team are keenly aware of the 
complex considerations involved in re-purposing the data for diverse 
ends and believe that further local quality checks are necessary, a point 
they also emphasize in their publications. As they note, manual curation 
is vulnerable to a set of “ascertainment biases” including publication 
bias (negative results are most often not published), population bias 
(research surges on populations of sudden interest) and sequencing bias 
(known cancer mutation hotspots are more likely to be the subject of 
further research) – all of which may skew COSMIC data in different ways 
(Forbes et al., 2006, 2008, 2016). Meanwhile, the automated curation of 
broad datasets can introduce different biases because of its lower reli-
ability in spotting inconsistencies and mistakes, and other limitations 
associated with sequencing (Forbes et al., 2015). Users are expected to 
implement a local process of quality control, and COSMIC includes 
source and sample references to facilitate this (Forbes et al., 2015; 
Sondka et al., 2018). 
COSMIC curators and users operate in different organisational 
contexts and there is no systematic communication between them. 
While some users endeavour to provide feedback and specific requests to 
the COSMIC team, the vast majority of the user base use COSMIC off the 
shelf. Most decisions taken by curators are of no interest to these users 
and are not reached via mechanisms of mutual accountability (such as 
outlined by Jasanoff, 2005). COSMIC curators envision the 
decision-making process as a distributed chain of scrutiny – but, given 
the constraints on interaction and fragmented accountability across the 
research landscape, worries about kinds of data re-use, risk and oppor-
tunity persist. To be able to use and benefit from the data, users need to 
trust COSMIC’s operational principles and procedures without having to 
repeat the data curation process. For the maintenance of a community 
standard and state-of-the-art database it is crucial that the COSMIC team 
is able to make judgments concerning curation targets and data sources, 
so as to relieve users from the burden of data curation. 
4. Data actionability between exploratory research and clinical 
diagnostics 
COSMIC releases data in two ways. First, data can be accessed via 
web browser, where a number of visualizations, search tools and hy-
perlinks allow the user to explore various relations between clinical 
observations. Users can select between available datasets, browse cancer 
genomes by location coordinates or toponymic categories (genes), and 
follow links to source publications. Second, users can download files of 
COSMIC data for integration into local systems and proprietary pipe-
lines. The data can then be used to run automated checks and compar-
isons against what are typically large quantities of data produced locally 
from cancer samples. Which data formats users end up using, and which 
suppositions allow them to trust the data and envision their action-
ability, depends on the specific problem spaces they work in and the 
operating assumptions and goals of their endeavours. We explore two 
kinds of situation: exploratory research and diagnostics development. 
4.1. The exploratory research space: understanding pathways 
Exploratory researchers rely on COSMIC in their endeavour of un-
derstanding the complex causal pathways that shape the evolution of 
cancer. It is now accepted that genetic drivers are most often expressed 
through complex gene networks, activation and expression triggers and 
patterns, protein products and environmental interactions. Working in a 
space saturated with large quantities of different kinds of data, all of 
which could be key, researchers’ concern is to avoid false positive leads. 
In exploratory research, actionable data are those that warrant positing 
a causal link between observable features (i.e., mutated sequences, or 
measurements of protein products) and cancer behaviour. They justify 
further investigation of new leads and the development of new disease 
impact hypotheses. Efforts include, among others, 1) testing the 
behaviour of small molecules on specific cell lines, with a view to 
selecting candidates for pharmaceutical development; but also 2) testing 
strategies and candidate drugs for treating the disease (i.e., ‘clinical’ 
research). 
Researchers in a pharmaceutical company may, for instance, be 
interested in the known implications of the mutated form of a certain 
gene. Some such mutations exhibit quite consistent behaviour. Web- 
based features of COSMIC provide a “high-level picture” of the gene 
that can be helpful, and the network of links and data made available for 
navigation is enormous and for many practical purposes inexhaustible. 
For instance, Rob McEwen, a pharmaceutical developer at Astra Zeneca, 
uses the web-based COSMIC browser to select patient populations to 
design drug trials. Web analytics features include distribution statistics 
of the kinds of cancer that carry a specific mutation. This helps users to 
select the patients that are most likely to carry cancers susceptible to 
targeted therapy. These counts are not population samples, i.e., they are 
not designed to represent proportions in the population of interest, but 
rather describe the distribution of mutations in the subset of the 
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published research data that has been analysed and integrated by 
COSMIC. Not all data about potentially relevant genes are curated, and 
the data that are available to COSMIC curators are not sampled by users. 
The lack of comprehensive statistical distributions notwithstanding, 
COSMIC counts are used as a best approximation. McEwen explains the 
key issue in designing basket trials as: “Each of [the compounds] has got a 
hypothesis around patient selection so that we know which patients to target 
depending on which mutations they harbour because then they’ll get the most 
benefit from that particular compound. So, we need to decide on the size of 
the patient segment in that cancer which is going to get the most benefit. 
Because there’s no use going into a cancer where there’s very few patients 
who’ve got the mutation that will respond to your drug. So that’s part of the 
work I do, looking at the prevalence of mutations in a particular cancer type 
to see whether there is an opportunity for a compound or a basket trial 
containing that compound in that particular cancer type” (P1). 
COSMIC may help inform further pharmaceutical development work 
when unexpected features of cancer emerge during clinical research 
(Vignola-Gagné et al., 2017), such as when a cancer develops resistance 
to a test drug. Insights from the clinical trial can then feed back into the 
pharmaceutical development pipeline. Researchers who download the 
COSMIC database can integrate it into proprietary sequencing pipelines 
and juxtapose it to new cancer sample sequences. McEwen illustrates: 
“In some cases then you find that a mutation may have gone really high, so 
there’s been a selection for a particular gene, or a mutation which has allowed 
the patient, then, to become resistant to the drug you’re testing. So then that 
can go back into the discovery, where you then start to look for a compound 
that inhibits that particular mutation and that gene that’s conferring the 
resistance to the drug that’s in the clinic.” (P1). 
COSMIC is also used to help determine whether newly observed 
mutations ‘have already been seen’, as another pharmaceutical 
researcher explains: “When we go in the clinical trials, we know that some 
patients are responding. Some are not responding. Then we do some kind of 
genotype of those patients; see what are the genomic differences between 
them. Some of the genomic changes, we want to see whether they have 
already been seen. If they have already been seen they must be in the COSMIC 
database, then we go back into the COSMIC database to check how much 
already is known and which are normal and which are not there” (P2). 
COSMIC is thus used as a census of research observations, the assump-
tion being that if a mutation has been seen, then it must be in COSMIC. 
Indeed, the warrant is quickly jeopardised in case of discordance with 
other sources. The informant explains: “If there is some kind of disagree-
ment between the databases, we might not go with that kind of gene. We think, 
‘Okay, we don’t trust either of the databases.’ So, we try to de-prioritise that.” 
(P2). 
Speculative reasoning about the epistemic value of COSMIC data is 
not something that actors do in isolation. It is something that researchers 
imagine to be assessed collectively by the broader community of cancer 
genomics. The database is envisioned as a space where the observations 
of the research community are shared and curatorial judgments made by 
COSMIC staff are regarded as a reliable assessment of the relevance of 
genes and mutations. In the words of McEwen “Quite often we have a long 
table of genes and mutations […] it’s useful then to […] remove anything 
that’s not in the cancer gene census [the COSMIC Cancer Gene Census is a 
list of mutated genes for which evidence is strongest of their implication 
in cancer – see Sondzka et al. 2018; Tempini, 2020a]. So, you’re only 
looking at cancer-relevant genes or ones where there’s a bit more of a layer of 
evidence that they might be cancer-related” (P1). Delegating evidence 
assessment to a trusted curatorial process enables cost-efficiency and 
adherence to community standards at once. 
4.2. The diagnostics development space: Locating reliable markers 
Diagnostics researchers seek to identify observable biological fea-
tures or events that can serve as reliable biomarkers. This often involves 
forgoing a full understanding of the causal pathways through which 
cancer evolves in favour of the identification of strong predictive signals. 
These must be robustly correlated with outcomes, and as early and 
discriminating as possible, to diagnose and treat patients while cancer is 
easier to kill and has had fewer chances to spread. A biomarker which 
predicts type, location and further evolution of cancer will facilitate the 
formulation of a tailored treatment regime. Here, actionable data are 
those that warrant a predictive association between measured feature 
and target outcome, where the latter can include cancer type, stage of 
advancement and/or preferred treatment. Diagnostics researchers we 
interviewed are working on a cutting-edge technique, liquid biopsy, that 
is considered highly promising. Small quantities of DNA released from 
cancer cells start circulating in the blood stream from the earliest stages 
of the disease. Liquid biopsy developers aim to intercept and charac-
terise this DNA to generate predictions. 
In this context, COSMIC data are considered actionable if they enable 
the identification of a genomic variant as reliable predictor of cancer 
trajectories. Using COSMIC data as a comparator helps to find clues 
about mutations of interest: “Are those previously reported mutations? Are 
they likely to be deleterious? And this is where COSMIC comes into play. It 
tells us whether others have found it before” (D1). This socialisation and 
intersubjectivity of observations strengthens the warrant that data 
confer to an interpretation. Users can trust their own observations 
because they are compatible with the observations of others, and 
because they can assume that to be trusted in turn. We saw in the pre-
vious section how exploratory research users emphasised the same 
point. These practices echo those reported in the sociology of witnessing 
(Shapin and Schaffer 1985): being able to use the data is a matter of 
being able to witness and to trust others’ witnessing. A diagnostics 
informant explains: “So you’ve seen something; somebody else has seen 
something, so that adds weight to the fact. You say, ‘Okay, it’s more likely to 
be real than just something random that I’ve seen, something random in the 
sequencing.’” 
Yet, diagnostics developers, too, are concerned about both false 
positives and false negatives (unnoticed sequences with high predictive 
power). They are particularly concerned that the data may not be 
comprehensive or statistically representative since they are trying to 
identify genotype–phenotype correlations. As an informant puts it: “The 
data were not representative of the true diversity of mutations in cancer. 
There was a bias towards mutations being tested a lot.” (D1). These users 
need to carefully examine COSMIC data, assessing their consistency with 
respect to their own knowledge of the state of the art and working hy-
potheses and assumptions. The presence of experts able to do this is key. 
Possible corrections can only be identified on the basis of personal 
experience: “It was useful but it, in a lot respects, wasn’t trustworthy, so you 
still had to do your own due diligence. […] we relied on the knowledge of 
people who’d spent a lot of time in the field of cancer. They had a good feel for 
what was real, what was not real. They knew what they knew. I did trust them 
that they had their finger on the pulse of the literature.” (D2). 
Given that a source of statistically representative cancer genomic 
data does not exist, users have to speculatively weigh the risks and re-
wards of using and scrutinizing COSMIC data. More complex questions 
about the very conceptualization of cancer and the causal assumptions 
underpinning the identification of specific mutations as cancer ‘drivers’ 
or ‘passengers’ are likely less relevant. Improving diagnostic tests’ by 
exploiting the ‘low-hanging fruits’ (i.e., efficiently interpreting the most 
common mutations) is seen as enough progress for the time being: 
“We’re young companies. So, you take the low hanging fruit first. You can see 
its obvious application, you get your pipeline set up, use it, and then yeah, 
maybe we’ll use [COSMIC] for further investigation” (D1). The extent to 
which the data will be relied upon is dependent on situated evaluations 
of opportunity, where the relative accessibility of available evidence, 
and the risks and advantages of adopting it, are weighed against one 
another. However, the presence of data in COSMIC that cannot be used 
does not undermine the high status accorded to the database and the 
curatorial work undertaken by its team. Crucially for our analysis, users 
draw a distinction between the trust they have in the fidelity with which 
COSMIC staff maintain their curatorial processes and standards, and the 
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degree of reliance that they are willing to invest in some data over 
another: “There’s plenty of expertise […] The bulk of the data is trustworthy. 
There are a few odd things I don’t trust myself either, but it’s uncommon” 
(D1). 
5. Actionability, trustworthiness and speculation 
An inviting contrast is emerging between notions of curation, 
actionability, trust and speculative reasoning in different kinds of cancer 
genomics research. As we have seen, in line with an emphasis on puta-
tive causal links between molecular makeup and cancer behaviour, 
exploratory researchers value a ‘high level picture’ of genes and muta-
tions. They highlight an interest in ‘derivative’ data (Tempini, 2020c) 
that consolidate and interpret large amounts of sequence data. They are 
also interested in ‘new’ mutations as they try to explain cancer behav-
iour (such as drug resistance) in the context of experiments with new 
targeted drugs, and resort to COSMIC as a database of ‘what has already 
been seen’ in their search for potentially responsible novelties. In 
contrast, diagnostics researchers emphasize mutation counts and prob-
lematise the relationship between COSMIC counts and real-world dis-
tributions. Their interest is in weighing the importance of mutations that 
have already been identified, and the clinical outcomes of those cases. 
This concerns not only the frequency of mutations but also the associ-
ated harms. As interesting as fleshing out this contrast would be, we 
leave this task to future research. In the remainder of this paper, we 
instead focus on explaining why exploratory and diagnostics users are 
nevertheless drawn to use COSMIC. Both kinds of research user are 
interested in the dynamics of collective seeing, so we turn our attention 
to explaining why researchers would use COSMIC as a reference to 
establish what has and what has not been seen. 
Practices of research evidence making, sharing and interpretation in 
cancer genomics have converged around a small number of standard 
databases. COSMIC is one of them and acts as a widely accepted point of 
reference, institutional memory of the research community, repository 
of witnessing, and off-the-shelf resource of computable data. A standard 
database helps to reduce local uncertainty in the many judgements 
involved in ascertaining whether cancer mutation data are relevant. At 
the same time, the routinization of a standard database carries risk: it 
delegates some interpretive choices that would otherwise be made by 
users and can make scrutiny of the data more difficult. Our interviewees 
often ignored the details and choices inherent in COSMIC’s curatorial 
processes (with respect to curation targets, prioritization of specific 
research trends and literature sources, and quality standards). They 
assumed that COSMIC provides a reliable census of evidence. Further, 
some users have invested in deep integration with COSMIC, developing 
capabilities and infrastructure in parallel with COSMIC in order to 
eschew the high running costs and uncertain returns involved in directly 
curating a database of research evidence. As one informant observed, 
“I’m not going to put someone to reanalyse TCGA for six months; that’s just 
not a good investment of time, in my opinion.” (D1). The incentive to rely so 
deeply on COSMIC is not limited to convenience and cost-efficiency 
gains in the local setting. The trustworthiness of COSMIC has been 
broadly sanctioned by the community. Familiarity to researchers, deep 
integration in technological platforms and pipelines, and community 
endorsement create a robust warrant for relying on the database. In the 
words of the diagnostics researcher who noted its longevity, “a lot of 
people are collecting data. COSMIC is the biggest, but it’s also one of the 
oldest, as in it’s been around, and people understand it” (D2). 
Yet, as previous noted by its director, COSMIC is built on the idea 
that in order to achieve reliable interpretations of cancer sequences, a 
degree of local judgement over the fitness for purpose of the data is 
required (see also Timmermans 2015). More generally, it is understood 
that a universal standard can thrive in different local contexts as long as 
it is under-specified so as to enable local adaptation through expert 
judgement (Berg and Timmermans 2000). However, local judgements 
about evidence concerning specific mutations do not resolve the 
uncertainty entailed in the curation and use of COSMIC data. Specula-
tive reasoning is unavoidable, but this is not scientific hypothesizing in 
the abstract, rather it is embedded in the organisational reality of pro-
cedures, routines, priorities, resource constraints, and business strate-
gies among other factors. While the choices of the COSMIC team aim to 
pre-empt user questions about the interpretation of the data, local 
adoption of the database makes users ask new questions about the 
context of COSMIC’s interpretations. 
There is thus a crucial interplay between speculative reasoning and 
reliance on COSMIC data, which shapes perceptions of data actionability 
and underpins the practice of cancer genomics. Whether users are able 
to regard COSMIC data as actionable depends on 1) the choice to trust 
the curatorial process that determines which data may be most valuable, 
which in turn requires speculative reasoning and risk-taking (by both 
curators and users) and 2) the judgment that specific COSMIC data are 
fit for purpose in each situation of genomic data interpretation. 
There is a difference between the two conditions. Hawley (2017) 
argues that individuals can be trusted, while organisations and objects 
can only be relied upon. This is because trust implies the possibility of 
betrayal or deception. For a COSMIC user it is thus reasonable to ask 
whether the curators can be trusted. As there is no reason to suspect the 
curators of deception, users trust that the curators are doing, give or 
take, as fine a job as they themselves would. The procedural principles 
guiding curation represent best practice and, most importantly, are 
promulgated on dedicated pages on the COSMIC website and in the 
team’s publications. The professional experience of curators supports 
the belief that their curation will be accurate and reliable. These are 
some of the reasons why a user might believe that COSMIC curators are 
trustworthy. Beyond that, the expectation is that any curatorial oddities 
will be errors, but not deceptions. 
Instead, COSMIC data, as objects, can only be relied upon, but not 
trusted (Hawley 2017). Data can be relied upon as epistemically sig-
nificant if the organisation generating them has made a commitment to 
purposefully designed standardised procedures (Hawley 2017), 
although reliance will depend also on assumptions about their suit-
ability for the problem at hand. Indeed, the commitment of the COSMIC 
team to explicit curatorial principles and goals warrants other re-
searchers and organisations’ reliance on the data. Users we interviewed 
cited episodes when the data were not relied upon because they did not 
appear accurate or sound. And yet, the fact that data may on occasion be 
faulty did not invalidate the main reasons for adopting COSMIC as a 
routine step in the sequence interpretation process. The separation be-
tween, on the one hand, placing trust in the curator who is handling the 
data and, on the other hand, reliance on curated data allows one to 
conceive of unreliable data and a trustworthy curator at once. We 
elaborate on these conditions of actionability in what follows, starting 
from the practices of speculative reasoning and trust. 
5.1. Speculative reasoning in data interpretation 
COSMIC curators process only a fraction of the data generated by the 
field. They make decisions regarding curation targets (e.g., genes most 
worthy of curation) and emerging opportunities (such as important 
research trends as well as new methods and kinds of data that curation 
could cover). They compile authoritative evidence summaries. Their 
curatorial decisions, which are by necessity speculative in their as-
sumptions about what is relevant, cannot fit everybody’s needs. Yet 
these decisions are key to the trustworthiness of the team and the 
COSMIC project as a whole. Users delegate to COSMIC important de-
cisions about data processing, and value its focused specialization and 
steady commitment to curation. COSMIC is valued not only for what it 
includes but also for what it excludes. In every user organisation, 
reasoning with COSMIC data involves evaluating how much of the data 
to rely upon and how much to deprecate through local validation (e.g., 
second checks with other resources, manual review). Using “imperfect” 
databases of genetic observations (Timmermans 2015) makes a degree 
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of risk unavoidable. Local expertise is required to lead the 
re-contextualization of data – Timmermans (2015) calls this reflexive 
standardization. Evaluating the actionability of data is, accordingly, a 
speculative judgement, but neither mere risk-taking nor discursive 
reasoning. Users concerned with the data’s lack of statistical represen-
tativeness speculate as they estimate the ‘true’ statistical ratios. Other 
users take COSMIC as a ‘census’ of observations (which it is not) to see if 
something ‘has already been seen’ and how often. The fact that users 
may ignore the details of COSMIC’s curation procedures highlights how 
constrained their deliberation is. Some users seem not to give much 
thought to the specific commitments to standardised procedures that, 
according to Hawley, warrants the epistemic significance of COSMIC’s 
assessments. A standard database that initially emerged in the commu-
nity thanks to its leadership in setting curatorial standards has thus 
become an obligatory passage point that is relied upon without detailed 
scrutiny of its assumptions and methodological choices. 
5.2. Trust in the database and reliance on data 
That the COSMIC database project is considered trustworthy even if 
the data are not always considered reliable highlights how speculative 
reasoning shapes attitudes of trust and evaluations of actionability. It is 
in this purview that the topic of speculative reasoning should be framed: 
not only as characterizing the epistemic practices of individual research 
organisations, but as the basic underpinning for a whole field that per-
forms data interpretation under conditions of high uncertainty. Simi-
larly to what Porter notoriously showed for numerical evidence (1995), 
and Timmermans argues in respect to genomic data (2015), a database 
such as COSMIC is used by the cancer research community as common 
ground upon which evidence, interpretations and discoveries can be 
assessed. If every research team compiled its own evidence base of 
cancer mutations, interpretations would be more difficult to scrutinize. 
As Porter observes (Porter 1995; Timmermans 2015), trusted standards 
emerge when the objectivity of the evidence shared within a research 
community is systematically questioned. The inability to rely on the data 
is therefore a pre-condition, not a limitation, for adopting specific re-
sources, methods and procedures as trusted standards for the production 
of objective evidence. In Porter’s seminal study, the favourable evalu-
ation of quantitative methodologies (typically consisting of repeatable 
processes through which numbers are produced) was a key step in the 
rise of numbers and quantitative evidence as a gold standard in several 
scientific and administrative fields. Trust was not invested in numbers 
per se but in the processes that reliably produced them. As Hawley 
similarly observes from a philosophical perspective (2017), organisa-
tional processes can be considered reliable and epistemically significant 
if an organisation is committed to operational principles designed to 
ensure reliability and earn trustworthiness. With respect to COSMIC, 
procedural standardization emerges as the key factor behind its success 
in attracting user trust, despite the sporadic lack of reliance on the data. 
Collecting and distributing publicly available data by following 
well-documented procedures and public commitments is a key step in 
the construction of objective sources of evidence. COSMIC’s circulation 
of standardised data across the community enables the use of data as a 
common point of reference in the generation, comparison and evalua-
tion of cancer sequence interpretations. Procedural standardization 
makes it possible for users to trust the database even when individual 
datasets are not seen as trustworthy in and of themselves. 
5.3. Speculation and trust 
Hawley (2019) defines trust as a combination of the trustor’s prac-
tical reliance on the trustee and the trustee’s commitment to fulfilling a 
specific task. Commitments can come into being, she notes, because: the 
trustee makes them; the trustor thinks that the trustee has made them; or 
the trustee allows the trustor to continue to rely upon her (2019:21). 
Because of the high level of uncertainty about the role of genetic 
sequences in the expression of phenotypical outcomes (Timmermans 
et al., 2017), users accept that error is possible in COSMIC’s curation 
processes. Uncertainty puts limits on expectations about what consti-
tutes fulfilment of COSMIC’s commitment to high quality curation. 
Procedural standardization gives weight to this commitment, securing 
trust in COSMIC. Trust in COSMIC is not based on the intrinsic qualities 
of data but rather on the alignment between the organisation and the 
user’s material and epistemic commitments. As Timmermans (2015) 
argues, despite the concerns that users have about the reliability of 
specific data, they remain dependent on sequence databases, and have 
limited ability to amend data, especially when their use is routinized. 
The process constrains the scrutiny that users can exercise. Operating 
procedures such as those performed by automated filters, algorithms 
and database schemas further embed standardised decisions into cancer 
genomics practice. 
6. Conclusion 
Our case study highlights a deep yet indirect interdependence be-
tween curation and data use in cancer genomics. Cancer genomics 
research depends on the collective actions of curators and users – actions 
that are imperfect, constrained by conditions of high uncertainty about 
the wider ecology of practices of the field and yet reflexive (albeit 
indirectly) about one another. Paying attention to organisational pro-
cedures, commitments and standards at both the curation and user sites, 
we emphasised the level of delegation that adoption of a database 
standard involves as an element that needs more consideration in the 
social studies of data curation. COSMIC is entrusted by researchers to 
provide an epistemic resource that can be relied upon to adhere to 
widely accepted standard procedures. In so doing, it provides a whole 
research domain with a centralised function of evidence aggregation, 
operationalising the assumption that empirical studies generate consis-
tent and comparable signals. 
When evaluating whether or not to rely on data, users need to 
consider the speculative judgments of COSMIC curators, together with 
methodological foibles associated with the data and the possibility of 
curatorial mistakes. Nevertheless, trusting COSMIC holds advantages for 
user organisations which go well beyond immediate convenience. A 
standard database such as COSMIC creates the opportunity for the 
cancer genomics field to share a collection of facts about cancer se-
quences (Cambrosio et al. 2020; Tempini 2020a). The existence of such a 
space, a database that aggregates findings in ways that make them 
concordant and comparable, makes it possible to assemble a coherent 
audience from a fragmented, distributed network of researchers 
communicating asynchronously and inconsistently through publications 
shared over the Internet. Echoing Anderson’s seminal analysis of the 
birth of national identities in imagined communities Anderson (2006), 
the database here contributes to the imagination of a community, which 
converges on specific means of communication and is involved in 
practices of collective witnessing – of ‘seeing’ and agreeing on what was 
seen. In contrast to 18th Century audiences of empirical witnesses, 
cancer genomics observations are convened by standardised evidence 
curation, aggregation and representation procedures. Although COSMIC 
data may occasionally contribute to a mistaken interpretation (be it due 
to uncertainty, curation error, or user error), this does not immediately 
undermine users’ trust in COSMIC. Instead, the routine consultation of a 
record of ‘what others have already seen’, compiled and dynamically 
maintained through trusted standardised procedures, becomes a key 
step in the transformation of user organisations’ local practices of 
sequence interpretation into standardised procedures. This is a strategic 
move by which user organisations assert their own trustworthiness 
(O’Neill, 2002). In the same vein as COSMIC retains trust despite caveats 
and imperfections, user organisations aim to demonstrate their own 
commitment to high standards of evidence to their own users by using 
COSMIC as a key component of their own sequence interpretation 
routines. 
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The actionability of cancer genomics data thus rests on a nested ar-
chitecture of dynamic, yet standardised, procedures of data manage-
ment (Cambrosio et al., 2020; Tempini and Leonelli 2018a), in which 
multiple organisations committed to demonstrating trustworthiness 
intervene in a sequence of operations of data management and inter-
pretation. Beyond the trust in standard procedures, little else is firm in 
this chain of custody (Wylie 2020; Tempini and Leonelli 2018b). These 
trustworthiness-seeking data management practices sit squarely at the 
heart of cancer genomics, making it possible to bear an increasing 
amount and diversity of data upon each other, while the chance for 
individual researchers to directly scrutinize sources is decreased. 
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